Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Metoprolol CR/XL in the treatment of chronic heart failure
Autore:
Gattis, WA;
Indirizzi:
Duke Univ, Med Ctr, Clin Res Inst, Durham, NC 27705 USA Duke Univ Durham NC USA 27705 ed Ctr, Clin Res Inst, Durham, NC 27705 USA
Titolo Testata:
PHARMACOTHERAPY
fascicolo: 5, volume: 21, anno: 2001,
pagine: 604 - 613
SICI:
0277-0008(200105)21:5<604:MCITTO>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONTROLLED-RELEASE METOPROLOL; ADRENERGIC-RECEPTOR BLOCKADE; PHARMACOKINETIC PROPERTIES; CONGESTIVE CARDIOMYOPATHY; BETA-BLOCKERS; HYPERTENSION; MORTALITY; DISEASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Gattis, WA Duke Univ, Med Ctr, Clin Res Inst, 2400 N Pratt St, Durham, NC 27705 USA Duke Univ 2400 N Pratt St Durham NC USA 27705 ham, NC 27705 USA
Citazione:
W.A. Gattis, "Metoprolol CR/XL in the treatment of chronic heart failure", PHARMACOTHE, 21(5), 2001, pp. 604-613

Abstract

Metoprolol CR/XL (metoprolol succinate extended-release tablets) is a beta(1)-selective agent that improved survival and reduced hospitalization among patients with New York Heart Association class II-IV heart failure in a randomized trial. Metoprolol CR/XL differs from conventional metoprolol tartrate with respect to pharmacokinetic and pharmacodynamic properties that may be clinically important in patients with heart failure. A thorough patient evaluation should be performed to determine optimal dosage and titrationof this drug, as with any beta -blocker, and to assess the potential for drug-drug or drug-disease interactions. By applying knowledge of drug-specific characteristics and designing therapy for each individual patient, improvement in patient outcomes can be realized with metoprolol CR/XL.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 03:49:15